argenex SE (NASDAQ:ARGX) Receives $1,016.22 Consensus PT from Analysts

argenex SE (NASDAQ:ARGX) has been given a consensus rating of “Moderate Buy” by the twenty-four analysts that are currently covering the company, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $1,016.2222.

A number of research firms have commented on ARGX. Wells Fargo & Company reduced their price target on argenex from $1,317.00 to $1,247.00 and set an “overweight” rating on the stock in a research report on Friday, February 27th. DZ Bank upgraded argenex to a “strong-buy” rating in a research report on Friday, December 19th. Guggenheim reduced their price target on argenex from $1,160.00 to $1,120.00 and set a “buy” rating on the stock in a research report on Friday, February 27th. Truist Financial upped their price target on argenex from $950.00 to $1,030.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of argenex in a research report on Wednesday, January 21st.

argenex Stock Down 1.5%

Shares of ARGX stock opened at $828.35 on Friday. The firm has a market capitalization of $51.51 billion, a P/E ratio of 42.44, a P/E/G ratio of 1.41 and a beta of 0.46. argenex has a twelve month low of $510.05 and a twelve month high of $934.62. The stock’s fifty day simple moving average is $765.40 and its 200 day simple moving average is $816.98.

argenex (NASDAQ:ARGX) last released its quarterly earnings results on Saturday, February 14th. The company reported $8.02 EPS for the quarter. argenex had a return on equity of 38.51% and a net margin of 30.42%. As a group, equities research analysts expect that argenex will post 3.13 EPS for the current fiscal year.

Institutional Investors Weigh In On argenex

A number of institutional investors have recently made changes to their positions in the stock. M&T Bank Corp lifted its stake in shares of argenex by 20,977.7% in the 4th quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock valued at $654,772,000 after purchasing an additional 774,916 shares during the period. Sands Capital Management LLC lifted its stake in shares of argenex by 2,046.6% in the 4th quarter. Sands Capital Management LLC now owns 356,870 shares of the company’s stock valued at $300,110,000 after purchasing an additional 340,245 shares during the period. Invesco Ltd. lifted its stake in shares of argenex by 390.4% in the 4th quarter. Invesco Ltd. now owns 416,408 shares of the company’s stock valued at $350,178,000 after purchasing an additional 331,489 shares during the period. Wellington Management Group LLP lifted its stake in shares of argenex by 80.1% in the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock valued at $538,408,000 after purchasing an additional 324,653 shares during the period. Finally, Two Sigma Investments LP lifted its stake in shares of argenex by 570.3% in the 3rd quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock valued at $216,961,000 after purchasing an additional 250,278 shares during the period. Institutional investors own 60.32% of the company’s stock.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.